Autism Research Advances Clash with Federal Committee's Outdated Focus

A new study in Science mapped protein interactions across autism risk genes, revealing shared biological pathways that could lead to new treatments. Meanwhile, the federal Interagency Autism Coordinating Committee approved a strategic plan that emphasizes debunked vaccine theories, according to an opinion piece. The author argues that the committee's priorities misdirect research funding away from promising genetic medicine developments.

EXPANDED:

The Science study represents a significant step in autism research, mapping over 1,800 protein-protein interactions across 100 risk genes. This work demonstrates that diverse genetic variations converge on shared biological pathways, potentially enabling treatments that address common mechanisms rather than individual mutations. Approximately one in five autistic individuals has an identifiable genetic cause.

Clinical trials for monogenic autism have shown early promise. An adult with UBE3A deletion spoke his first word after receiving an antisense oligonucleotide, while a child in an SCN2A trial experienced a 90% reduction in seizures. The IACC plan instead emphasizes neurodevelopmental regression and medical injury models, which critics argue misdirects limited